Andrew W. Hutcheon - Concepedia

Author

Andrew W. Hutcheon

Also Known As

A Hutcheon, A W Hutcheon, A. HUTCHEON, A. Hutcheon, A. W. HUTCHEON, A. W. Hutcheon, A.W Hutcheon, A.W. Hutcheon, AW Hutcheon, Andrew Hutcheon

Publications

5.1K

Citations

H-Index

Concepts

All Affiliations

University of Aberdeen Aberdeen Royal Infirmary NHS Grampian University of Glasgow Western Infirmary

About

Andrew W. Hutcheon is an author at University of Aberdeen specializing in medicine, oncology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	39	3.8K
2	Health Sciences	8	8	1.8K
3	Engineering	2	2	446
4	Nursing	2	2	88
5	Social Sciences	1	1	71

Andrew W. Hutcheon

Publications

4.8K

Citations

H-Index

Page 1

	Year	Citations
A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival Keith N. Ogston, Iain D. Miller, Simon Payne, The Breast Surgical OncologyBreast OncologyPathologyCancer RegistrationPrognostic Significance	2003	969
Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response With Docetaxel Ian C. P. Smith, Steven D. Heys, Andrew W. Hutcheon, Journal of Clinical Oncology Breast OncologyCancer ManagementPharmacotherapyCancer ChemotherapyCpr Rate	2002	434
Positron Emission Tomography Using [<sup>18</sup>F]-Fluorodeoxy-<scp>d</scp>-Glucose to Predict the Pathologic Response of Breast Cancer to Primary Chemotherapy Ian C. P. Smith, A. Welch, Andrew W. Hutcheon, Journal of Clinical Oncology Surgical OncologyEngineeringBreast OncologyOncologic ImagingPathology	2000	409
Psychological, clinical and pathological effects of relaxation training and guided imagery during primary chemotherapy Liz Walker, Mary B. Walker, Keith N. Ogston, British Journal of Cancer	1999	223
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy Anna Jones, A Hill, David Cunningham, The Lancet Emetogenic ChemotherapyOncologyMetronomic TherapyPharmacologyPharmacotherapy	1991	217
Neoadjuvant Docetaxel in Breast Cancer: 3-Year Survival Results from the Aberdeen Trial Steven D. Heys, Andrew W. Hutcheon, Tarun K. Sarkar, Clinical Breast Cancer Breast OncologyOncologyBreast CancerNeoadjuvant DocetaxelCancer Treatment	2002	178
Recurrent aphthae: treatment with vitamin B12, folic acid, and iron. D. Walter Wray, M.M. Ferguson, D K Mason, BMJ Iron MetabolismDeficienciesin Vitamin B12Clinical EpidemiologyHematologyPathology	1975	174
Phase III Randomized Trial of Doxorubicin and Docetaxel Versus Doxorubicin and Cyclophosphamide As Primary Medical Therapy in Women With Breast Cancer: An Anglo-Celtic Cooperative Oncology Group Study T.R. Jeffry Evans, Ann Yellowlees, E. Foster, Journal of Clinical Oncology	2005	173
Cutaneous malignant melanoma, Scotland, 1979-89 R.M. MACKIE, T Aitchison, John Hunter, The Lancet Cutaneous Malignant MelanomaSurgical OncologyMelanomaHistopathologyPathology	1992	157
Cutaneous malignant melanoma in Scotland: incidence, survival, and mortality, 1979-94 R.M. MACKIE, D. Hole, John Hunter, BMJ	1997	157

Page 1